WUXI BIO(02269)
25.900-0.450-1.71%
Market data delayed 15 minutes
Login to post
- CommunityCommunity
- NewsNews
- ProfileProfile
- AnnouncementsAnnouncements
- BRIEF-WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025BRIEF-WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025
Reuters · 11:48
- WuXi Biologics' Profit Slides 1.3% in 2024WuXi Biologics' Profit Slides 1.3% in 2024
MT Newswires Live · 10:55
- BRIEF-WuXi Biologics Posts FY Revenue Of RMB18,675.4 MlnBRIEF-WuXi Biologics Posts FY Revenue Of RMB18,675.4 Mln
Reuters · 08:45
- WuXi Biologics (Cayman) Inc. (HKG:2269) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable
Simply Wall St. · 03-16
WuXi Biologics (Cayman) Inc. (HKG:2269) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable - Greater China Stocks Close Mixed; Hong Kong Leads GainersGreater China Stocks Close Mixed; Hong Kong Leads Gainers
Dow Jones · 03-14
- WuXi Biologics Included in S&P Global Sustainability Yearbook 2025WuXi Biologics Included in S&P Global Sustainability Yearbook 2025
THOMSON REUTERS · 03-11
- WuXi Biologics (Cayman) Inc.'s (HKG:2269) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Simply Wall St. · 03-04
WuXi Biologics (Cayman) Inc.'s (HKG:2269) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects? - Greater China Stocks Slip; Taiwan Sees Largest DeclineGreater China Stocks Slip; Taiwan Sees Largest Decline
Dow Jones · 02-24
- Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$30.59 From HK$19.30, Keeps at BuyNomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$30.59 From HK$19.30, Keeps at Buy
MT Newswires Live · 02-20
- WuXi Biologics (Cayman) (HKG:2269) earnings and shareholder returns have been trending downwards for the last three years, but the stock ascends 9.4% this past week
Simply Wall St. · 02-15
WuXi Biologics (Cayman) (HKG:2269) earnings and shareholder returns have been trending downwards for the last three years, but the stock ascends 9.4% this past week - China's Healthcare Sector Could Ride the AI Wave -- Market TalkChina's Healthcare Sector Could Ride the AI Wave -- Market Talk
Dow Jones · 02-14
- China hawk to be picked for key US Commerce Dept job, sources sayChina hawk to be picked for key US Commerce Dept job, sources say
Reuters · 02-12
- Stock Track | Wuxi Biologics Soars 6.82% Intraday as UOB Kay Hian Upgrades to BuyStock Track | Wuxi Biologics Soars 6.82% Intraday as UOB Kay Hian Upgrades to Buy
Stock Track · 02-04
- UOB Kay Hian Upgrades Wuxi Biologics to Buy from Sell, Price Target is HK$23UOB Kay Hian Upgrades Wuxi Biologics to Buy from Sell, Price Target is HK$23
MT Newswires Live · 02-04
- WuXi Biologics (Cayman) Inc.'s (HKG:2269) P/E Is On The Mark
Simply Wall St. · 01-25
WuXi Biologics (Cayman) Inc.'s (HKG:2269) P/E Is On The Mark - Investor Confidence on WuXi Companies Seems Stronger -- Market TalkInvestor Confidence on WuXi Companies Seems Stronger -- Market Talk
Dow Jones · 01-20
- BUZZ-China's WuXi XDC rises on robust results forecastBUZZ-China's WuXi XDC rises on robust results forecast
Reuters · 01-15
- China Healthcare Sector to Get Policy Boost in 1Q -- Market TalkChina Healthcare Sector to Get Policy Boost in 1Q -- Market Talk
Dow Jones · 01-07
- WuXi Biologics (Cayman) Subsidiary to Sell Vaccines Manufacturing Facility in Ireland for $500 MillionWuXi Biologics (Cayman) Subsidiary to Sell Vaccines Manufacturing Facility in Ireland for $500 Million
MT Newswires Live · 01-07
- WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 MillionWuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 Million
Dow Jones · 01-07
Company Profile
Company NameWUXI BIOMarketSEHKEstablishment Date- -Employees- -Office Location- -WebsiteZip Code- -Phone- -Fax- -IntroductionWuXi Biologics (Cayman) Inc is an investment holding company principally engaged in the provision of end-to-end solutions and services for biologics discovery, development and manufacturing to customers involving in biologics industry. The Company mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The Company mainly conducts its business in the domestic and overseas markets.
- 1D
- 5D
- Day
- Week
- Month
High
26.450
Open
26.150
Volume%
0.64
Low
25.250
Close
26.350
T/O Rate
0.83%
抱歉，当前请求异常(-1)
Terms and Conditions·Privacy Policy
Company: TTMF Limited. Tech supported by Xiangshang Yixin.
Email：uservice@ttm.financial